Ex) Article Title, Author, Keywords
Ex) Article Title, Author, Keywords
Pharmacoepidemiology and Risk Management 2023; 15(1): 1-10
Published online March 31, 2023 https://doi.org/10.56142/perm.23.0001
Copyright © Korean Society for Pharmacoepidemiology and Risk Management.
Boyoon Choi1, Ha Young Jang2,3, Hye-Ryun Kang4, Jung Mi Oh3
최보윤1, 장하영2,3, 강혜련4, 오정미3
Correspondence to:Boyoon Choi
College of Pharmacy and Institute of Pharmaceutical Sciences, CHA University, 120 Haeryong-ro, Donggyo-dong, Pocheon 11160, Korea
Tel: +82-31-850-9443
Fax: +82-31-850-9315
E-mail: boyoon1@cha.ac.kr
This is an Open-Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Therapeutic monoclonal antibodies (TmAbs) are new treatment options for cancer. While their use is more common, hypersensitivity reactions (HSRs) to these drugs have been increased, preventing the use of first-line therapies. The aim of this review is to update and discuss the HSRs to TmAbs in their clinical features and management. Type 1 hypersensitivity is the most common type of the HSRs to TmAbs, followed by cytokine release reactions (CRRs) and type 4 hypersensitivity. Mixed reactions of various types might also occur. TmAbs can have different immunogenicity depending on their non-human epitope contents, target proteins, and solubilizing additives. It may be also affected by the patient’s baseline condition and the number of administrations. When HSRs occur, it is recommended to classify the mechanism into type 1/type 4 hypersensitivity and CRRs. A skin test and desensitization are generally the most useful management for type 1 hypersensitivity but there is no standardized protocol for TmAbs yet. Readministration is contraindicated in type 4 hypersensitivity reactions and supportive care is effective in CCRs. Understanding the characteristics and measures for each HSRs may be helpful to ensure the safe use of anticancer monoclonal antibodies.
KeywordsMonoclonal antibodies, Antineoplastic agents, Hypersensitivity, Skin test, Desensitization
